Company intelligence / Profile preview
VLP Therapeutics
Gaithersburg, Maryland, United Statesvlptherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
The company has multiple vaccine candidates in development, with their COVID-19 self-amplifying RNA vaccine in Phase 3, malaria vaccine (VLPM-01) in Phase 2, and cancer vaccine (VLPONC-01) in Phase 1. They are also developing preclinical vaccines for dengue and other cancers.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Virus-like particle vaccinesmRNA vaccinesSelf-amplifying RNA vaccinesProphylactic vaccinesTherapeutic vaccinesRecombinant polypeptides
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on VLP Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLP Therapeutics.